Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07223658 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 9 months later Sep 30, 2026 → Jul 2027
See other at-risk trials from Arrowhead Pharmaceuticals

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary completion pushed from Sep 30, 2026 to Jul 2027
    • Study sites: 17 to 19
    • Eligibility criteria expanded, about 9 words
    • Secondary endpoints: details revised at 3 of 15 entries
  2. Study sites: 15 to 17v6
  3. Primary completion pushed from Jun 2026 to Sep 30, 2026
    • Trial sites expanded: 11 → 15 locations
    v5
  4. Study sites: 9 to 11v4
  5. Trial sites expanded: 1 → 9 locationsv3
  6. Trial status: Not Yet Recruiting to Recruiting
    • Primary completion date: Jul 2027 to Jun 2026
    • Study sites: 0 to 1
    • Start date changed from estimate of Dec 2025 to Dec 22, 2025
    v2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD), and effects on low-density lipoprotein cholesterol (LDL-C) and triglycerides (TGs) of single-dose ARO-DIMERPA and multiple doses of ARO-DIMERPA in adult participants with mixed hyperlipidemia.
Trial Details
NCT Number NCT07223658
Lead Sponsor Arrowhead Pharmaceuticals
Conditions
(from sponsor)		 Hyperlipidemia; Mixed
Related terms Hyperlipoproteinemia Type II
Enrollment 78 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov